Jpmorgan Chase & CO Chimerix Inc Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Chimerix Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,539 shares of CMRX stock, worth $1,492. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,539

Previous 1,539 -0.0%

Holding current value

$1,492

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$0.91 - $1.26 $182,913 - $253,265	-201,004 Reduced 99.24%	1,539 $1,000
Q4 2023 Feb 12, 2024	BUY	$0.9 - $1.06 $179,214 - $211,074	199,127 Added 5829.24%	202,543 $194,000
Q3 2023 Nov 14, 2023	SELL	$0.94 - $1.23 $300,882 - $393,708	-320,088 Reduced 98.94%	3,416 $3,000
Q2 2023 Aug 11, 2023	SELL	$1.1 - $1.54 $28,297 - $39,616	-25,725 Reduced 7.37%	323,504 $391,000
Q1 2023 May 18, 2023	BUY	$1.19 - $2.09 $76,755 - $134,805	64,500 Added 22.65%	349,229 $440,000
Q1 2023 May 11, 2023	SELL	$1.19 - $2.09 $247,491 - $434,669	-207,976 Reduced 42.21%	284,729 $358,000
Q4 2022 Feb 13, 2023	BUY	$1.67 - $2.35 $740,123 - $1.04 Million	443,188 Added 895.02%	492,705 $916,000
Q3 2022 Nov 14, 2022	SELL	$1.81 - $2.76 $2,367 - $3,610	-1,308 Reduced 2.57%	49,517 $96,000
Q2 2022 Aug 11, 2022	BUY	$1.34 - $5.34 $5,640 - $22,476	4,209 Added 9.03%	50,825 $107,000
Q1 2022 May 11, 2022	BUY	$4.58 - $6.8 $39,017 - $57,929	8,519 Added 22.36%	46,616 $213,000
Q4 2021 Feb 10, 2022	SELL	$5.23 - $7.18 $170,717 - $234,369	-32,642 Reduced 46.14%	38,097 $245,000
Q3 2021 Nov 12, 2021	BUY	$5.94 - $8.75 $420,189 - $618,966	70,739 New	70,739 $437,000

Others Institutions Holding CMRX

# of Institutions

Shares Held

36.8M

Call Options Held

72.2K

Put Options Held

169K

View Full List

About CHIMERIX INC

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

More about CMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Chimerix Inc Transaction History